These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10365591)

  • 1. Increased circulating granulocyte colony-stimulating factor in acute Kawasaki disease.
    Inoue Y; Kato M; Kobayashi T; Shinohara M; Sone K; Morikawa A
    Pediatr Int; 1999 Jun; 41(3):330-3. PubMed ID: 10365591
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies of peripheral blood toxic neutrophils as a predictor of coronary risk in Kawasaki disease--the pathogenetic role of hematopoietic colony-stimulating factors (GM-CSF, G-CSF).
    Takeshita S; Sekine I; Fujisawa T; Yoshioka S
    Acta Paediatr Jpn; 1990 Oct; 32(5):508-14. PubMed ID: 1704677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serum granulocyte colony-stimulating factor correlates with coronary artery dilatation in Kawasaki disease.
    Samada K; Igarashi H; Shiraishi H; Hatake K; Momoi MY
    Eur J Pediatr; 2002 Oct; 161(10):538-41. PubMed ID: 12297900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of neutrophil activation cytokines in Kawasaki disease.
    Suzuki H; Noda E; Miyawaki M; Takeuchi T; Uemura S; Koike M
    Pediatr Int; 2001 Apr; 43(2):115-9. PubMed ID: 11285059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum M-CSF levels in Kawasaki disease.
    Oana S; Terai M; Kohno Y
    Br J Haematol; 1999 Nov; 107(2):462-3. PubMed ID: 10583242
    [No Abstract]   [Full Text] [Related]  

  • 6. High serum levels of M-CSF and G-CSF in Kawasaki disease.
    Igarashi H; Hatake K; Tomizuka H; Yamada M; Gunji Y; Momoi MY
    Br J Haematol; 1999 Jun; 105(3):613-5. PubMed ID: 10354120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased macrophages, high serum M-CSF and low serum cholesterol in myelodysplasia and Kawasaki disease.
    Shetty V; Allampallam K; Raza A
    Br J Haematol; 1999 Sep; 106(4):1068. PubMed ID: 10520017
    [No Abstract]   [Full Text] [Related]  

  • 8. [Enhanced neutrophilic functions in mucocutaneous lymph node syndrome (MCLS). With special reference to the possible role of increased active oxygen generation in the pathogenesis of coronary thromboarteritis].
    Niwa Y; Yanagida I; Somiya K
    Rinsho Ketsueki; 1984 May; 25(5):619-26. PubMed ID: 6471444
    [No Abstract]   [Full Text] [Related]  

  • 9. Impaired granulocyte chemotaxis and increased circulating immune complexes in Kawasaki disease.
    Ono S; Onimaru T; Kawakami K; Hokonohara M; Miyata K
    J Pediatr; 1985 Apr; 106(4):567-70. PubMed ID: 3981310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
    Tsujimoto H; Takeshita S; Nakatani K; Kawamura Y; Tokutomi T; Sekine I
    Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
    Abe J; Ebata R; Jibiki T; Yasukawa K; Saito H; Terai M
    J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating soluble L-selectin levels in Kawasaki disease with coronary artery lesions.
    Hirao J; Yamashita T
    Acta Paediatr Jpn; 1997 Apr; 39(2):290-2. PubMed ID: 9141275
    [No Abstract]   [Full Text] [Related]  

  • 13. Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease.
    Sakai M; Asayama K; Otabe T; Kohri T; Shirahata A
    Clin Appl Thromb Hemost; 2001 Jul; 7(3):214-8. PubMed ID: 11441982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating soluble CD23 levels in Kawasaki disease with coronary artery lesions.
    Hirao J; Yamashita T
    Acta Paediatr Jpn; 1997 Jun; 39(3):397-9. PubMed ID: 9241913
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased CD11b expression on polymorphonuclear leucocytes and cytokine profiles in patients with Kawasaki disease.
    Kobayashi T; Kimura H; Okada Y; Inoue Y; Kobayashi T; Shinohara M; Morikawa A
    Clin Exp Immunol; 2007 Apr; 148(1):112-8. PubMed ID: 17286760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kawasaki disease and oxidative metabolism.
    Lebranchu Y; Malvy D; Richard MJ; Arnaud J; Favier A; Bardos P
    Clin Chim Acta; 1990 Mar; 187(3):193-8. PubMed ID: 2108832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antioxidant enzymes and lipoperoxide in blood in patients with Kawasaki disease. Comparison with the changes in acute infections.
    Uchida N; Asayama K; Dobashi K; Hayashibe H; Kato K
    Acta Paediatr Jpn; 1990 Jun; 32(3):242-8. PubMed ID: 2239296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The many faces of Kawasaki syndrome.
    Leung DY; Meissner HC
    Hosp Pract (1995); 2000 Jan; 35(1):77-81, 85-6, 91-4. PubMed ID: 10645991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary neopterin as a predictive marker of coronary artery abnormalities in Kawasaki syndrome.
    Iizuka T; Minatogawa Y; Suzuki H; Itoh M; Nakamine S; Hatanaka Y; Uemura S; Koike M
    Clin Chem; 1993 Apr; 39(4):600-4. PubMed ID: 8472352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Kawasaki syndrome in autoimmune neutropenia after treatment with granulocyte colony-stimulating factor.
    Ueno K; Nomura Y; Arata M; Maruyama S; Tanabe T; Eguchi T; Kawano Y
    Pediatr Int; 2011 Jun; 53(3):388-90. PubMed ID: 21696506
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.